38
Participants
Start Date
August 31, 2014
Primary Completion Date
February 15, 2017
Study Completion Date
February 15, 2017
SGN-CD70A
Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester
University of Pennsylvania / Perelman Center for Advanced Medicine, Philadelphia
UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill
Medical University of South Carolina/Hollings Cancer Center, Charleston
University of Alabama at Birmingham, Birmingham
Case Western Reserve University / University Hospitals Case Medical Center, Cleveland
University of Cincinnati Cancer Institute, Cincinnati
University of Michigan Comprehensive Cancer Center, Ann Arbor
Karmanos Cancer Institute / Wayne State University, Detroit
Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood
Methodist Cancer Center, Houston
University of Texas Health Science Center at San Antonio, San Antonio
Texas Oncology - Austin Midtown, Austin
Comprehensive Cancer Centers of Nevada, Las Vegas
Northwest Cancer Specialists, P.C., Vancouver
City of Hope National Medical Center, Duarte
Seattle Cancer Care Alliance / University of Washington, Seattle
Seagen Inc.
INDUSTRY